AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27919589 — intervention group
Group type: COMPARATOR
Intervention: Control (Groups I, II, III)
Number of subjects: 80
Study 24930639 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP + MTZ (400 mg TID) + AMX (500 mg TID) for 14 days
Number of subjects: 58
Study 24930639 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP + MTZ + AMX
Number of subjects: 58
Study 24930639 — intervention group
Group type: COMPARATOR
Intervention: SRP alone
Number of subjects: 58
Study 22446291 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity interval training (IT) consisting of 3 sessions of 12 repetitions of 30 seconds of exercise at very high intensity, followed by 60 seconds of complete rest.
Number of subjects: 26
Study 22446291 — intervention group
Group type: COMPARATOR
Intervention: Continuous training (CT) consisting of 45 minutes of aerobic exercise.
Number of subjects: 26
Study 20958856 — intervention group
Group type: EXPERIMENTAL
Intervention: 980 nm InGasAs diode laser (power 15 W, spot size 8 mm, time 3 seconds, fluence 90 J/cm(2)) applied weekly for 9 weeks
Number of subjects: 34
Study 20958856 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 34
Study 20958856 — intervention group
Group type: EXPERIMENTAL
Intervention: 980 nm InGasAs diode laser
Number of subjects: 34
Study 20958856 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 34
Study 17910603 — intervention group
Group type: COMPARATOR
Intervention: sustained-release melatonin
Number of subjects: 44
Study 16086149 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic opioid therapy
Number of subjects: 80
Study 16086149 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic opioid therapy with antidepressant
Number of subjects: 80
Study 12135028 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (40 mg p.o. every 12 h)
Number of subjects: 101
Study 12135028 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic ethanol injection therapy
Number of subjects: 101
Study 10396712 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 2 mg/kg
Number of subjects: 30
Study 10396712 — intervention group
Group type: COMPARATOR
Intervention: Thiamylal 4 mg/kg
Number of subjects: 30
Study 10468248 — intervention group
Group type: EXPERIMENTAL
Intervention: A4 (28,572 KIU/kg of aprotinin before surgery, followed by continuous infusion of 7,143 KIU/kg/h until the end of surgery)
Number of subjects: 59
Study 10468248 — intervention group
Group type: EXPERIMENTAL
Intervention: A2 (14,286 KIU/kg of aprotinin before surgery, followed by continuous infusion of 7,143 KIU/kg/h until the end of surgery)
Number of subjects: 59
Study 10468248 — intervention group
Group type: COMPARATOR
Intervention: C (control group, no aprotinin)
Number of subjects: 59
Study 10468248 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including A2, A4, and C)
Number of subjects: 59
Study 10468248 — intervention group
Group type: EXPERIMENTAL
Intervention: A4
Number of subjects: 59
Study 10468248 — intervention group
Group type: COMPARATOR
Intervention: A2 and C
Number of subjects: 59
Study 1859488 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous cyclophosphamide
Number of subjects: 111
Study 1859488 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cyclophosphamide
Number of subjects: 111
Study 1859488 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral azathioprine plus cyclophosphamide
Number of subjects: 111
Study 1859488 — intervention group
Group type: COMPARATOR
Intervention: Prednisone only
Number of subjects: 111
Study 6303373 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol 200 mg in a slow‐release tablet once daily for 4 days and 10 mg i.v. shortly before induction of anaesthesia
Number of subjects: 40
Study 6303373 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 1.0‐1.5 mg during anaesthesia
Number of subjects: 40
Study 6303373 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets and physiological saline i.v.
Number of subjects: 40
Study 6303373 — intervention group
Group type: COMPARATOR
Intervention: Saline i.v. instead of fentanyl or naloxone
Number of subjects: 40
Study 31468618 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-dose bevacizumab therapy (7.5 mg/kg every 3-4 weeks)
Number of subjects: 4
Study 29496069 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab or Bevacizumab in combination with fluorouracil, folinic acid, and irinotecan (first-line therapy)
Number of subjects: 400
Study 29496069 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of enlarged lymph nodes
Number of subjects: 400
Study 26353946 — intervention group
Group type: EXPERIMENTAL
Intervention: Limited open carpal tunnel release
Number of subjects: 84
Study 26353946 — intervention group
Group type: COMPARATOR
Intervention: Short wrist transverse open carpal tunnel release
Number of subjects: 84
Study 25479324 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation (FES) during isometric contractions
Number of subjects: 8
Study 25479324 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation (FES) during recovery intervals
Number of subjects: 8
Study 23082055 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 83
Study 23082055 — intervention group
Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 83
Study 20180011 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 124
Study 18685524 — intervention group
Group type: EXPERIMENTAL
Intervention: Explosive resistance training for 8 weeks
Number of subjects: 49
Study 18685524 — intervention group
Group type: EXPERIMENTAL
Intervention: Young training group
Number of subjects: 49
Study 18685524 — intervention group
Group type: COMPARATOR
Intervention: Control groups (young and old)
Number of subjects: 49
Study 18685524 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 49
Study 15833780 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol/remifentanil
Number of subjects: 50
Study 15833780 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane/remifentanil
Number of subjects: 50
Study 12431965 — intervention group
Group type: EXPERIMENTAL
Intervention: Marimastat 10 mg orally bid for up to 2 years
Number of subjects: 532
Study 12431965 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 532
Study 10344347 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril therapy
Number of subjects: 14
Study 8950069 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided antiarrhythmic therapy (class I, II, and III antiarrhythmic drugs)
Number of subjects: 196
Study 8950069 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 196
Study 1758710 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-Controlled Analgesia (PCA)
Number of subjects: 20
Study 1758710 — intervention group
Group type: COMPARATOR
Intervention: Continuous Infusion (CI)
Number of subjects: 20
Study 6759059 — intervention group
Group type: EXPERIMENTAL
Intervention: timolol/hydrochlorothiazide/amiloride preparation
Number of subjects: 641
Study 6759059 — intervention group
Group type: COMPARATOR
Intervention: cyclopenthiazide/potassium
Number of subjects: 641
Study 6759059 — intervention group
Group type: EXPERIMENTAL
Intervention: both treatments
Number of subjects: 641
Study 31152039 — intervention group
Group type: EXPERIMENTAL
Intervention: User-centred clinical decision support (CDS) system integrated into ED clinician electronic workflow
Number of subjects: 20
Study 31152039 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 20
Study 28727223 — intervention group
Group type: EXPERIMENTAL
Intervention: Abacus-based mental calculation (AMC) training, 2 hours per week
Number of subjects: 0
Study 28727223 — intervention group
Group type: COMPARATOR
Intervention: Control group (no abacus experience)
Number of subjects: 0
Study 28727223 — intervention group
Group type: EXPERIMENTAL
Intervention: Abacus-based mental calculation (AMC) training
Number of subjects: 0
Study 26031762 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized fentanyl (250 μg)
Number of subjects: 14
Study 26031762 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 26031762 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest wall strapping (CWS)
Number of subjects: 14
Study 24214779 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.15 mg/kg morphine sulfate
Number of subjects: 200
Study 24214779 — intervention group
Group type: COMPARATOR
Intervention: 0.10 mg/kg morphine sulfate
Number of subjects: 200
Study 24214779 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 21745374 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG) 0.4 g/kg/day for 5 days
Number of subjects: 41
Study 21745374 — intervention group
Group type: COMPARATOR
Intervention: Plasma exchange (PE) one volume daily for 5 days
Number of subjects: 41
Study 21745374 — intervention group
Group type: EXPERIMENTAL
Intervention: CSF protein
Number of subjects: 41
Study 19966527 — intervention group
Group type: EXPERIMENTAL
Intervention: Lornoxicam (LOR) 8 mg
Number of subjects: 45
Study 19966527 — intervention group
Group type: EXPERIMENTAL
Intervention: Lornoxicam (LOR) 16 mg
Number of subjects: 45
Study 19966527 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (untreated patients)
Number of subjects: 45
Study 17445841 — intervention group
Group type: COMPARATOR
Intervention: Surgical treatment (early surgery)
Number of subjects: 0
Study 17445841 — intervention group
Group type: COMPARATOR
Intervention: Stereotactic aspiration technique
Number of subjects: 0
Study 17445841 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopy for hematoma removal
Number of subjects: 0
Study 15477634 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole 2.5 mg once daily
Number of subjects: 907
Study 15477634 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen 20 mg once daily
Number of subjects: 907
Study 11581551 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine (CRT)
Number of subjects: 22
Study 11581551 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo (PLC)
Number of subjects: 22
Study 11581551 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 22
Study 9824265 — intervention group
Group type: EXPERIMENTAL
Intervention: Terlipressin (2 mg/day for 2 days)
Number of subjects: 9
Study 9824265 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 7646609 — intervention group
Group type: EXPERIMENTAL
Intervention: hCG supplementation
Number of subjects: 81
Study 7646609 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 2144941 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA-rich pollock oil
Number of subjects: 8
Study 2144941 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA-rich tuna or salmon-blend oils
Number of subjects: 8
Study 2144941 — intervention group
Group type: COMPARATOR
Intervention: Butter diet
Number of subjects: 8
Study 6446778 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous spectinomycin hydrochloride (8 g per day)
Number of subjects: 17
Study 6446778 — intervention group
Group type: COMPARATOR
Intervention: Aqueous penicillin G (2.0 x 10(7) units per day, iv) plus kanamycin (1 g per day, im)
Number of subjects: 17
Study 31522218 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex (Group S)
Number of subjects: 70
Study 31522218 — intervention group
Group type: COMPARATOR
Intervention: Neostigmine + Atropine (Group N)
Number of subjects: 70
Study 28812402 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise program with behavioral change support
Number of subjects: 12
Study 25979573 — intervention group
Group type: EXPERIMENTAL
Intervention: Type D personality
Number of subjects: 84
Study 25979573 — intervention group
Group type: EXPERIMENTAL
Intervention: Low self-efficacy
Number of subjects: 84
Study 25979573 — intervention group
Group type: EXPERIMENTAL
Intervention: Type D personality with self-efficacy included
Number of subjects: 84
Study 23379537 — intervention group
Group type: EXPERIMENTAL
Intervention: OC000459 (100 mg, twice daily)
Number of subjects: 26
Study 23379537 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 21110526 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab 80 mg at baseline followed by 40 mg every other week from week 1 to week 15
Number of subjects: 0
Study 21110526 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 0
Study 21110526 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19466961 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose UVB therapy (40% incremental doses, three times weekly)
Number of subjects: 109
Study 19466961 — intervention group
Group type: COMPARATOR
Intervention: Low-dose UVB therapy (20% incremental doses, three times weekly)
Number of subjects: 109
Study 17699479 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemocontrol (HC) system
Number of subjects: 44
Study 17699479 — intervention group
Group type: COMPARATOR
Intervention: Standard HD
Number of subjects: 44
Study 15107485 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic mesh repair
Number of subjects: 2164
Study 15107485 — intervention group
Group type: COMPARATOR
Intervention: Open mesh repair
Number of subjects: 2164
Study 15107485 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 2164
Study 15107485 — intervention group
Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 2164
Study 15107485 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic repair of primary hernias
Number of subjects: 2164
Study 15107485 — intervention group
Group type: COMPARATOR
Intervention: Open repair of recurrent hernias
Number of subjects: 2164
Study 11495180 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (30 or 60 mg) with behavioral counseling
Number of subjects: 989
Study 11495180 — intervention group
Group type: COMPARATOR
Intervention: Placebo with behavioral counseling
Number of subjects: 989
Study 9721156 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg igmesine
Number of subjects: 16
Study 9721156 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg igmesine
Number of subjects: 16
Study 9721156 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 8036824 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal purified chick embryo cell rabies vaccine (PCEC) alone (0.1 ml at each of two sites on days 0, 3, and 7, and at one site on days 28 and 90) (n = 81)
Number of subjects: 133
Study 8036824 — intervention group
Group type: COMPARATOR
Intervention: Intradermal PCEC with one dose of human rabies immunoglobulin (HRIG) intramuscularly at 20 IU kg‐1 on day 0 (n = 52)
Number of subjects: 133
Study 2730948 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine gum
Number of subjects: 0
Study 2730948 — intervention group
Group type: COMPARATOR
Intervention: Placebo gum
Number of subjects: 0
Study 1256687 — intervention group
Group type: EXPERIMENTAL
Intervention: 2‐Mercapto‐Priopionyl‐Glycine (2‐MPG) plus B12 vitamin
Number of subjects: 80
Study 1256687 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus B12 vitamin
Number of subjects: 80
Study 31295363 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein (PRO) diet
Number of subjects: 13
Study 31295363 — intervention group
Group type: COMPARATOR
Intervention: High-carbohydrate (CHO) diet
Number of subjects: 13
Study 27959715 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclisiran (300 mg or more, single dose)
Number of subjects: 8
Study 27959715 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclisiran (100 mg or more, single dose)
Number of subjects: 8
Study 27959715 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclisiran (multiple doses)
Number of subjects: 8
Study 27959715 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 26189484 — intervention group
Group type: EXPERIMENTAL
Intervention: HAL-PDT (hexyl 5‐aminolevulinate‐hydrochloride)
Number of subjects: 40
Study 26189484 — intervention group
Group type: COMPARATOR
Intervention: Clobetasol propionate 0.05% ointment (corticosteroid group)
Number of subjects: 40
Study 26189484 — intervention group
Group type: EXPERIMENTAL
Intervention: HAL-PDT
Number of subjects: 40
Study 26189484 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 24204065 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (weekly for up to 14 weeks)
Number of subjects: 226
Study 20650985 — intervention group
Group type: EXPERIMENTAL
Intervention: Online spirometry performed by remote technicians
Number of subjects: 261
Study 20650985 — intervention group
Group type: COMPARATOR
Intervention: Conventional spirometry
Number of subjects: 261
Study 20650985 — intervention group
Group type: EXPERIMENTAL
Intervention: Online spirometry
Number of subjects: 261
Study 19414946 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 50 mg/day for 6 months
Number of subjects: 361
Study 19414946 — intervention group
Group type: COMPARATOR
Intervention: Vitamin B-12 500 mcg/day
Number of subjects: 361
Study 16888038 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain plasticity-based training program
Number of subjects: 0
Study 16888038 — intervention group
Group type: COMPARATOR
Intervention: Matched active control group
Number of subjects: 0
Study 16888038 — intervention group
Group type: COMPARATOR
Intervention: No-contact control group
Number of subjects: 0
Study 15581649 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain
Number of subjects: 146
Study 15581649 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress
Number of subjects: 146
Study 15581649 — intervention group
Group type: EXPERIMENTAL
Intervention: Assistance from friends
Number of subjects: 146
Study 15581649 — intervention group
Group type: EXPERIMENTAL
Intervention: Understanding from friends
Number of subjects: 146
Study 11738300 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT)
Number of subjects: 25
Study 9340957 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Number of subjects: 97
Study 9340957 — intervention group
Group type: COMPARATOR
Intervention: Collar immobilisation for 3 weeks
Number of subjects: 97
Study 9340957 — intervention group
Group type: COMPARATOR
Intervention: Control group (50 healthy persons with the same age and sex distribution)
Number of subjects: 97
Study 8329880 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjoint therapy component in social-learning-based alcoholism treatment
Number of subjects: 0
Study 8329880 — intervention group
Group type: COMPARATOR
Intervention: Social-learning-based alcoholism treatment without conjoint therapy
Number of subjects: 0
Study 8329880 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjoint treatment with high-autonomy alcoholics
Number of subjects: 0
Study 8329880 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment without other family members for low-autonomy alcoholics
Number of subjects: 0
Study 3525077 — intervention group
Group type: EXPERIMENTAL
Intervention: Busulfan (4-6 mg/day during 4-8 weeks, with re-administration at relapse)
Number of subjects: 293
Study 3525077 — intervention group
Group type: COMPARATOR
Intervention: 32P (0.5-1 mCi/10 kg at diagnosis and for each overt relapse)
Number of subjects: 293
Study 29072342 — intervention group
Group type: EXPERIMENTAL
Intervention: Protected areas
Number of subjects: 5000
Study 29072342 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term data analysis
Number of subjects: 5000
Study 29072342 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term data analysis
Number of subjects: 5000
Study 27403046 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric sulfate
Number of subjects: 90
Study 27403046 — intervention group
Group type: EXPERIMENTAL
Intervention: Buffered glutaraldehyde
Number of subjects: 90
Study 27403046 — intervention group
Group type: EXPERIMENTAL
Intervention: Mineral trioxide aggregate (MTA)
Number of subjects: 90
Study 24299006 — intervention group
Group type: EXPERIMENTAL
Intervention: ProRoot MTA
Number of subjects: 80
Study 24299006 — intervention group
Group type: EXPERIMENTAL
Intervention: Dycal
Number of subjects: 80
Study 24299006 — intervention group
Group type: COMPARATOR
Intervention: Small pulp exposure areas (<5 mm²)
Number of subjects: 80
Study 24299006 — intervention group
Group type: COMPARATOR
Intervention: Large pulp exposure areas (>5 mm²)
Number of subjects: 80
Study 22456602 — intervention group
Group type: EXPERIMENTAL
Intervention: Six times per week hemodialysis (Daily Trial)
Number of subjects: 332
Study 22456602 — intervention group
Group type: COMPARATOR
Intervention: Three times per week hemodialysis (Daily Trial)
Number of subjects: 332
Study 22456602 — intervention group
Group type: EXPERIMENTAL
Intervention: Six times per week nocturnal hemodialysis (Nocturnal Trial)
Number of subjects: 332
Study 22456602 — intervention group
Group type: COMPARATOR
Intervention: Three times per week conventional hemodialysis (Nocturnal Trial)
Number of subjects: 332
Study 19863578 — intervention group
Group type: EXPERIMENTAL
Intervention: Carisbamate 400 mg/day
Number of subjects: 1127
Study 19863578 — intervention group
Group type: EXPERIMENTAL
Intervention: Carisbamate 200 mg/day
Number of subjects: 1127
Study 19863578 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1127
Study 18034847 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 300 mg
Number of subjects: 40
Study 18034847 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 18034847 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 100 mg
Number of subjects: 40
Study 15826611 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarified appearance question (e.g., 'What does the sponge look like?')
Number of subjects: 3
Study 15826611 — intervention group
Group type: COMPARATOR
Intervention: Standard appearance-reality task
Number of subjects: 3
Study 14587161 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 1
Study 14587161 — intervention group
Group type: COMPARATOR
Intervention: Classical catecholamines (dopamine and dobutamine)
Number of subjects: 1
Study 10821721 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 100 microg bid
Number of subjects: 37
Study 10821721 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 250 microg bid
Number of subjects: 37
Study 10821721 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37